The selective estrogen enzyme modulator (SEEM) in breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 76, Issue 1-5, 2001, Pages 95-104

  Chetrite, G S ^a   Pasqualini, J R ^a  

^a Hormones and Cancer Research Unit   (France)

Author keywords

17 Hydroxysteroid dehydrogenase; Breast cancer; Progestins; Sulfatase; Sulfotransferase

Indexed keywords

16ALPHA ETHYL 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; 4 HYDROXYTAMOXIFEN; 4 METHYLCOUMARIN 7 O SULFAMATE; ANASTROZOLE; AROMATASE; COUMARIN DERIVATIVE; CYTOCHROME P450; ENZYME INHIBITOR; ESTRADIOL; ESTRONE; ESTRONE 3 O SULFAMATE; ESTRONE DERIVATIVE; ESTRONE SULFATASE; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NOMEGESTROL ACETATE; NORETHISTERONE; ORG 30126; ORG 4090; ORG 4094; ORG OM 38; PROGESTERONE; PROMEGESTONE; SULFATASE; SULFOTRANSFERASE; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; TIBOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER TISSUE; CELL LINE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONAL THERAPY; HORMONE SYNTHESIS; HUMAN; HUMAN CELL;

17-HYDROXYSTEROID DEHYDROGENASES; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; HUMANS; PROGESTERONE; SULFATASES;

EID: 0034982135     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00046-2     Document Type: Conference Paper

References (71)

1. Hormones and mammary carcinogenesis
2. The role of hormones in the development of human breast cancer
3. Estrogens as a cause of human cancer, The Richard and Hinda Rosenthal Foundation Award Lecture
4. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue
5. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
6. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer
7. Concentrations of estrone, estradiol, and their sulfates and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma
8. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues
9. Aromatization of androgens by human breast cancer
10. The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue
11. Aromatase activity in primary and metastatic human breast cancer
12. Steroid sulfatase activities in human breast tumors
13. Effects of plasma estrogen sulfates in mammary cancer cells
14. Estrogen sulfates: Biological and ultrastructural responses and metabolism in MCF-7 human breast cancer cells
15. The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells
16. Importance of estrogen sulfates in breast cancer
17. Estradiol 17β-dehydrogenase and estradiol binding in human mammary tumors
18. The relationship between 17β-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue
19. 3H-œstradiol by normal breast and breast tumour tissues in post-menopausal women
20. In situ estrogen production via the estrone sulfatase pathway in breast tumors: Relative importance versus the aromatase pathway
21. Conjugation of steroid hormones by normal and neoplastic tissues
22. Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma
23. Steroid sulphotransferase activity in human hormone-independent MDA-MB-468 mammary cancer cells
24. Aromatase inhibitors and treatment of breast cancer
25. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer
26. Aromatase inhibitors
27. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor Vorozole
28. In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma
29. Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer
30. Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: A hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence
31. Effect of the progestagen Promegestone (R-5020) on mRNA of the œstrone sulphatase in the MCF-7 human mammary cancer cells
32. Biological effects and morphological responses to estriol, estriol-3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R-27) derived from MCF-7 human breast cancer cells
33. Effect of tamoxifen and tamoxifen derivatives on the conversion of estrone sulfate to estradiol in the MCF-7 mammary cancer cell line
34. Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs. independent human breast cancer cell lines
35. Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens
36. Effect of promegestone, tamoxifen, 4-hydroxytamoxifen and ICI 164,384 on the œstrone sulphatase activity of human breast cancer cells
37. Effect of the progestagen R-5020 (Promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in the MCF-7 and T-47D human mammary cancer cells: Correlation with progesterone receptor levels
38. Effect of nomegestrol acetate on estrone-sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer cells
39. Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines
40. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells
41. Recent advances in the development of steroid sulphatase inhibitors
42. In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor
43. Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkylamines as non-steroidal estrone sulfatase inhibitors
44. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate
45. In vivo inhibition of œstrone sulphatase and dehydroepiandrosterone sulphatase by œstrone-3-O-sulphamate
46. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application
47. Control and expression of oestrone sulphatase activities in human breast cancer
48. Comparison of the in vitro conversion of estradiol-17β to estrone of normal and neoplastic human breast tissue
49. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture
50. 17β-Hydroxysteroid dehydrogenase activity in human breast epithelial cells and fibroblast cultures
51. Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020)
52. 17β-Hydroxysteroid dehydrogenase (E2DH) activity in T47D cells
53. Estradiol 17β-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency
54. Effect of medrogestone on 17β-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines
55. Steroidal regulation of œstradiol-17β-dehydrogenase activity of the human breast cancer cell line MCF-7
56. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17β-hydroxysteroid dehydrogenase activity
57. Androgen receptor-mediated stimulation of 17β-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells
58. Progestin induction of 17β-hydroxysteroid dehydrogenase enzyme protein in the T-47D human breast cancer cell line
59. Effects of Org OD14 (Livial®) and its metabolites on 17β-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells
60. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer
61. 4-Hydroxyandrostenedione treatment for post-menopausal patients with advanced breast cancer
62. Steroid modulation of aromatase activity in human cultured breast carcinoma cells
63. Oestrogen sulphotransferases in malignant and normal human breast tissue
64. Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines
65. Identification and characterization of cytosolic sulfotransferase activities in MCF-7 human breast carcinoma cells
66. Steroid sulfotransferases
67. Human estrogen sulfotransferase (hEST1) activities and its mRNA in various breast cancer cell lines, effect of the progestin, promegestone (R-5020)
68. Effect of Org OD14 (Livial®) and its metabolites on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T-47D, and the hormone-independent MDA-MB-231 breast cancer cell lines
69. The relationship between breast cancer survival and prior postmenopausal estrogen use
70. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients